A- A A+

Yee Chao (趙毅)

  • 2875-7270
Yee Chao(趙毅)


  1. 國立陽明大學 臨床醫學研究所 博士
  2. 高雄醫學大學 醫學系 醫學士
經歷 現職:
  1. 2016- 迄今 臺北榮民總醫院 腫瘤醫學部 部主任
  2. - 迄今 國立陽明大學 醫學院 教授
  1. 2014- 2016 臺北榮民總醫院 勞工安全衛生室 室主任
  2. 1998- 2014 臺北榮民總醫院 癌病中心 藥物放射治療科 科主任
  3. 1990- 1998 臺北榮民總醫院 內科部 胃腸科 主治醫師
  4. - 臺北榮民總醫院 內科部 胃腸科 臨床研究員
  1. 胃癌,肝癌,胰臟癌,消化系腫瘤,大腸癌,食道癌
  1. 中華民國醫師執照、內科專科醫師、台灣臨床腫瘤醫學會臨床專科醫師、消化系內科專科醫師、消化系內視鏡專科醫師
  1. 英文



  1. Chao Y*, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY.  The Combination of Transcatheter Arterial Chemoembolization and Sorafenib is Well Tolerated and Effective in Asian Patients with Hepatocellular Carcinoma: Final Results of the START Trial. Int J Cancer 2015 Mar; 136(6): 1458-67. (IF: 5.531; Oncology 29/213)

  2. Chou WC, Lin PH, Yeh YC, Shyr YM, Fang WL, Wang SE, Liu CY, Chang PM, Chen MH, Hung YP, Li CP, Chao Y*, Chen MH*.  Genes Involved in Angiogenesis and mTOR Pathways Are Frequently Mutated in Asian Patients with Pancreatic Neuroendocrine Tumors. Int J Biol Sci 2016 Nov; 12(12): 1523-32. (IF: 3.982; Biochemistry & Molecular Biology 78/289)

  3. Hung YP, Liu CJ, Hu YW, Chen MH, Li CP, Yeh CM, Chiou TJ, Chen TJ, Yang MH, Chao Y*.  Secondary Primary Malignancy Risk in Patients with Ovarian Cancer in Taiwan: A Nation-Wide Population-Based Study. Medicine (Baltimore) 2015 Sep; 94(38): e1626. (IF: 2.133; Medicine, General & Internal 40/155)

  4. Fang WL, Hung YP, Liu CJ*, Lan YT, Huang KH, Chen MH, Lo SS, Shyr YM, Wu CW, Yang MH, Chen TJ, Chao Y*.  Incidence of and Risk Factors for Tuberculosis (TB) in Gastric Cancer Patients in an Area Endemic for TB: A Nation-Wide Population-Based Matched Cohort Study. Medicine (Baltimore) 2015 Nov; 94(47): e2163. (IF: 2.133; Medicine, General & Internal 40/155)

  5. Tseng CL, Lai WJ, Huang CJ, Huang YH, Su CW, Lee IC, Tseng HS, Li CP, Lee RC, Lin HC, Chao Y*.  The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan. Medicine (Baltimore) 2015 Nov; 94(47): e1659. (IF: 2.133; Medicine, General & Internal 40/155)

  6. Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP*, Chao Y*.  A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed By Docetaxel Plus Capecitabine in Patients with Unresectable Gastric Adenocarcinoma: the TCOG 3211 Clinical Trial. Medicine (Baltimore) 2016 Jan; 95(3): e2565. (IF: 2.133; Medicine, General & Internal 40/155)

  7. Lee TY, Lin CC, Chen CY, Wang TE, Lo GH, Chang CS, Chao Y*.  Combination of Transcatheter Arterial Chemoembolization and Interrupted Dosing Sorafenib Improves Patient Survival in Early-Intermediate Stage Hepatocellular Carcinoma: A Post Hoc Analysis of the START Trial. Medicine (Baltimore) 2017 Sep; 96(37): e7655. (IF: 1.803; Medicine, General & Internal 58/154)

  8. Hung YP, Chen MH, Lin JS, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y*.  The Clinical Impact of the Novel Tumor Marker DR-70 in Unresectable Gastric Cancer Patients. J Chin Med Assoc 2018 Jul; 81(7): 593-8. Epub 2018 Apr. (IF: 1.252; Medicine, General & Internal 82/154)

  9. Chen MH, Kuo YJ, Yeh YC, Lin YC, Tzeng CH, Liu CY, Chang PM, Chen MH, Jeng YM, Chao Y*.  High Neuroendocrine Component is a Factor for Poor Prognosis in Gastrointestinal High-Grade Malignant Mixed Adenoneuroendocrine Neoplasms. J Chin Med Assoc 2015 Aug; 78(8): 454-9. Epub 2015 May. (IF: 1.013; Medicine, General & Internal 88/155)